Clinical trials: Normal Population
Dry Eye
Mucin Levels in Dry Eye and Normal Populations
The purpose of this study is to evaluate changes in ocular mucin levels in response to a drying environment in subjects with dry eye disease as well as patients who report no history of dry eye disease.
- Trial name
- NCT05911555
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Primary Pulmonary Hypertension
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT03992755
- Testing
- LIQ861 Inhaled Treprostinil
- Where
- 25 sites in United States
- Volunteers
- 92 people
- Sponsor
- Liquidia Technologies, Inc.
Actinic Keratoses
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.
- Trial name
- NCT00942604
- Testing
- PEP005 (ingenol mebutate) Gel, Vehicle gel
- Where
- 17 sites in United States
- Volunteers
- 203 people
- Sponsor
- Peplin
Melanoma, Cutaneous Malignant, Mucosal Melanoma
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the…
- Trial name
- SUPRAME (NCT06743126)
- Testing
- IMA203, nivolumab plus relatlimab, lifileucel
- Where
- 71 sites in United States, Canada and 4 more
- Volunteers
- 450 people
- Sponsor
- Immatics US, Inc.
Actinic Keratosis (AK)
A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period
Once or twice daily 12 week treatment in patients with Actinic Keratosis randomized to treatment in one of four arms.
- Trial name
- NCT03116698
- Testing
- Low dose DFD07 once daily, High dose DFD07 once daily, High dose DFD07 twice daily
- Where
- 20 sites in United States
- Volunteers
- 240 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Healthy Volunteer, Renal Impairment
Study of AT-527 in Subjects With Normal and Impaired Renal Function
Study of AT-527 in Subjects with Normal and Impaired Renal Function
- Trial name
- NCT05618314
- Testing
- AT-527, AT-527 and Probenecid
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Atopic Dermatitis
Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis
The purpose of this study is to evaluate the effect of Cetaphil® Restoraderm® skin restoring moisturizer in reducing the signs and symptoms of very dry atopic skin in young children.
- Trial name
- NCT02589392
- Testing
- Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash, Cetaphil® Restoraderm® body wash
- Where
- 8 sites in China, Philippines
- Volunteers
- 120 people
- Sponsor
- Galderma R&D
Arthritis, Rheumatoid
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy
This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period.
- Trial name
- NCT00611455
- Testing
- ofatumumab
- Where
- 45 sites in Argentina, Australia and 11 more
- Volunteers
- 265 people
- Sponsor
- GlaxoSmithKline
Acne Vulgaris
Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel
Marketed by Galderma Laboratories, L.P., Differin® (adapalene 0.3% topical gel) is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01095640
- Testing
- adapalene 0.3% topical gel
- Where
- India
- Volunteers
- 1,159 people
- Sponsor
- Actavis Mid-Atlantic LLC
Rheumatoid Arthritis
A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
This is a phase III, randomized, controlled, double-blind, parallel group, international study in approximately 750 patients with active Rheumatoid Arthritis (RA) who are naive to Methotrexate (MTX) therapy.
- Trial name
- IMAGE (NCT00299104)
- Testing
- folate, methotrexate, methylprednisolone
- Volunteers
- 755 people
- Sponsor
- Genentech, Inc.
Scabies
Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.
This is a multi-center, double-blind, randomized, two arm parallel design study. This study is comprised of two phases: screening and treatment.
- Trial name
- NCT02978508
- Testing
- Permethrin Cream, 5%, Elimite
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- Mayne Pharma International Pty Ltd
Psoriatic Arthritis
VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)
The objective of this study is to evaluate if VTX958 is safe and effective in adult participants with active Psoriatic Arthritis.
- Trial name
- NCT05715125
- Testing
- Dose A VTX958, Dose B VTX958
- Where
- 46 sites in United States, Bulgaria and 5 more
- Volunteers
- 205 people
- Sponsor
- Ventyx Biosciences, Inc
Eczema
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to <12 years of age who have moderate-to-severe eczema.
- Trial name
- NCT06807268
- Testing
- Abrocitinib
- Where
- 47 sites in United States, China and 6 more
- Volunteers
- 150 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)
The purpose of this study is to determine if CH-4051 is a safe and effective treatment for rheumatoid arthritis.
- Trial name
- MOTION (NCT01116141)
- Testing
- CH-4051, Methotrexate (MTX), Folic Acid
- Volunteers
- 250 people
- Sponsor
- Chelsea Therapeutics
Psoriasis, Pruritus
Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable Mild Plaque Psoriasis, Dry Skin and Pruritus
The product RL3020-DP0364 developed by Pierre Fabre Laboratories moisturizes durably and repairs dry or atopic skin, especially in the case of certain dermatoses (atopic dermatitis, ichthyosis, etc ...) and erythema induced by…
- Conditions
- Psoriasis, Pruritus, Dry Skin
- Trial name
- NCT06800755
- Testing
- Dexeryl (RL3020-DP0364)
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Tinea Pedis, Athlete's Foot
Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis
This is a study of the safety and efficacy of Econazole Nitrate Foam 1% and the Foam Vehicle in subjects with interdigital tinea pedis (athlete's foot between the toes).
- Trial name
- NCT01358240
- Testing
- Econazole Nitrate Foam 1%, Vehicle Foam, Econazole Nitrate Cream 1%
- Where
- 12 sites in United States
- Volunteers
- 336 people
- Sponsor
- AmDerma
Rheumatoid Arthritis
A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab
This is a Phase II, randomized, active-controlled, double-blind, double-dummy, parallel-group, multicenter study in the United States enrolling patients with active RA.
- Trial name
- NCT00808210
- Testing
- Infliximab, Methotrexate, Methylprednisolone
- Where
- 53 sites in United States
- Volunteers
- 28 people
- Sponsor
- Genentech, Inc.
Psoriasis
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT01208090
- Testing
- ACT-128800
- Where
- 67 sites in Austria, Belgium and 15 more
- Volunteers
- 326 people
- Sponsor
- Actelion
Neurodermatitis
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
Primary Objective: To demonstrate the efficacy of dupilumab on itch response in participants with prurigo nodularis (PN), inadequately controlled on topical prescription therapies or when those therapies are not advisable.
- Trial name
- NCT04183335
- Testing
- Dupilumab SAR231893, Moisturizers, Low to medium potent topical corticosteroids
- Where
- 63 sites in United States, Argentina and 6 more
- Volunteers
- 151 people
- Sponsor
- Sanofi
Actinic Keratosis
Bioequivalence Study of Two Imiquimod Cream 5%
The primary objectives are to establish the therapeutic equivalence of imiquimod cream 5%, manufactured by Taro Pharmaceuticals Inc.
- Trial name
- NCT00828568
- Testing
- Imiquimod 5% manufactured by Taro, Aldara - Imiquimod 5%, Imiquimod Vehicle manufactured by Taro
- Where
- 20 sites in United States
- Volunteers
- 425 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.